Company ProfilePremium

TalkMed Group Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
TalkMed Group Limited - Company showcase

Year Founded & Workforce

2013

270 Employees

TalkMed Group Limited logo

TalkMed Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

TalkMed Group Limited Overview

TalkMed is a doctor-founded, asset-light specialist oncology services platform. Its core business is supplying medical oncologists, haematologists and clinical staff to Parkway Cancer Centre. Parkway Cancer Centre is a division of Parkway Hospitals Singapore that operates across Gleneagles, Mount Elizabeth, Mount Elizabeth Medical Centre and Mount Elizabeth Novena.

The model is unusual among listed healthcare companies:

  • It earns consultancy and management fees under a long-standing agreement with Parkway rather than owning hospitals.

  • This produced operating margins near 45–50% and a debt-free balance sheet holding S$80–90M of cash.

The franchise rests on the clinical reputation of four founder doctors led by Dr Ang Peng Tiam. This is both its key differentiator and its principal concentration risk.

Around the core, TalkMed built small regional oncology outposts in Vietnam and China and a cell and gene therapy contract manufacturing unit (CellVec). In September 2025 it became the Singapore anchor of Tamarind Health, a Templewater- and Temasek-backed pan-Asian oncology platform.


Company's own description (FY2024 Annual Report, paraphrased)

The company described itself as a premier provider of three services, serving patients in Singapore and the region:

  • medical oncology

  • stem cell transplants

  • palliative care

Outside Singapore it operated in Vietnam, Hong Kong (until the 2024 divestment by its associate) and the People's Republic of China. The FY2024 Annual Report also states:

  • SCC is among the market leaders in Singapore medical tourism.

  • Foreign patients accounted for more than half of its patient load in recent years.

  • Many of those patients came from Indonesia, Malaysia and Vietnam.

How the business makes money

The FY2024 results announcement (Note 4) describes two reportable segments. A third segment existed until FY2021.

1. Oncology services (94.1% of FY2024 revenue), earned in two ways:

Consultancy services: - SCC supplies specialist doctors and clinical staff to Parkway Cancer Centre (PCC). Revenue is computed under the Consultancy Restatement Agreement with Parkway Hospitals Singapore Pte. Ltd.

  • The Group supplies consultancy to Thu Cuc International General Hospital in Hanoi under a profit-sharing agreement.

  • It provides consultancy to patients directly in Beijing (TalkMed Shanshui Medical Centre) and Chongqing (Sino-Singapore Cancer Centre).

Management fees: SCC bills PCC for the salaries, wages, benefits and premises rental incurred in delivering oncology services. It also recovers expenses of SCC doctors serving Thu Cuc. This is largely a cost pass-through.

2. Cellular and gene therapy (CGT) products and services (5.9% of FY2024 revenue):

  • CellVec Pte. Ltd. (60%) manufactures GMP-grade lentiviral vectors for CAR-T and other cell therapies used in clinical trials.

  • BioCell Innovations Pte. Ltd. (60%) began operations in 2024 but booked no revenue that year.

3. Stem cell related products and services (discontinued):

  • Stem Med Pte. Ltd. (55.2%) provided stem cell processing and storage until it was divested in October 2021.

Revenue model mix

Revenue typeFY2024Share of total
Oncology consultancy services (service fees)44.7057.2%
Oncology management fees (cost-recovery service)28.8636.9%
CGT products and services (product/contract manufacturing)4.615.9%
Total78.18100.0%

There is no subscription or licensing revenue. Almost all revenue (S$77.76M in FY2024) is recognised over time as services are rendered.

Value-chain position, customers and end-markets

AspectDetail
Direct contractual customer for most revenueParkway Hospitals Singapore, part of IHH Healthcare
Economic end-customersSelf-paying and insured cancer patients from Singapore and the region
CGT customersBiotech companies, research institutes and large pharmaceutical companies in Australia, the US, New Zealand and elsewhere (FY2024 Annual Report)
End-marketsPrivate oncology and haematology in Singapore; regional medical tourism (Indonesia, Malaysia, Vietnam); private oncology in Beijing and Chongqing; cell and gene therapy contract manufacturing

TalkMed sits at the physician-services layer of the private oncology value chain:

  • It controls the clinical relationship with the patient and the doctor talent.

  • It does not own the hospital infrastructure, pharmacy or wards, which belong to Parkway.

Independent characterisation

Analytically, TalkMed functioned as a capital-light, talent-centric professional partnership wrapped in a listed company:

Assets: its assets were its doctors' reputations and the Parkway contract. Fixed assets were minimal: PPE S$4.36M and right-of-use assets S$4.36M at end-FY2024.

Margins and capital intensity: EBITDA margins of 47–54% (derived, FY2020–FY2024) and capex below 1% of revenue in most years.

Payouts: the model supported dividend payouts of 70–130% of attributable profit.

The weaknesses are equally structural:

Founder dependence: revenue tracks the founder doctors (51.7% of FY2024 revenue, down from 68.2% in FY2020).

Single-doctor dependence: Dr Ang alone generated 31.8% of FY2024 revenue.

Policy exposure: the business is sensitive to Singapore health-financing policy, notably the Cancer Drug List introduced September 2022.

Weak diversification: every diversification attempt to date — China, Hong Kong, stem cells, CGT — consumed capital and produced losses or, at best, a one-off gain on exit.

Strategy

Stated strategy before privatisation (FY2024 Annual Report, results commentary and AGM, paraphrased)

Vision and mission: to be a premier private-sector provider of medical oncology and palliative care in Singapore and the region, eventually expanding into primary and secondary care.

Singapore:

  • Expand the foreign-patient base as regional air connectivity improves.

  • Optimise processes to absorb higher volumes.

  • Manage the impact of the Cancer Drug List; management expected local demand to stabilise and grow steadily in 2025.

China:

  • Grow patient numbers through operational improvement.

  • Collaborate with established hospitals and insurers.

  • Recruit experienced doctors and introduce differentiated services.

  • Increase visits to the China centres by Singapore experts.

Cell and gene therapy:

  • CellVec to broaden its client base (biotech, research institutes, pharma) and services, targeting stronger 2025 growth.

  • BioCell to start compassionate-use and safety CAR-T programmes in India.

ESG targets for FY2025:

  • Maintain carbon-emissions intensity.

  • At least 40 training hours per employee.

  • Zero fatalities, reportable injuries, corruption cases and data breaches.

  • Run a gap analysis against the ISSB S2 climate-disclosure standard.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDetail
Aug 2024Portfolio rationalisationExit from Hong Kong via HKH's sale of HKIOC; investment de-recognised at 31 Dec 2024
23 Dec 2024Strategic combinationAgreement for Tamarind Health to acquire TalkMed
2,025China premises relocationA China subsidiary was due to move to new premises in 2025
Sep 2025Integration into Tamarind HealthTamarind's stated rationale: sub-specialisation, shared infrastructure, research collaboration and clinical trials, streamlined billing, and a Singapore medical-tourism hub. TalkMed was to continue operating under its current brand.
Oct 2025Platform positioningTamarind describes itself as a doctor-led integrated oncology platform: more than 180,000 patient visits a year, more than 500 doctors and staff, 36 centres
Sep 2026Rare Cancer CentreTamarind launches a single access point for rare and complex cancers (haematologic malignancies and lymphoma, sarcoma, neuroendocrine tumours, brain and uncommon skin cancers), drawing on network oncologists
Long termPotential relistingThe joint announcement stated the combined entity may consider a future SGX listing

Medium-term financial targets / guidance

  • TalkMed never published quantitative medium-term targets. Guidance was qualitative ("cautiously optimistic"; "steady growth anticipated").

  • Tamarind Health does not publish financial guidance.

  • Not publicly disclosed.

Products & Services

Oncology services segment

OfferingDescriptionTarget customerSincePricing model
Parkway Cancer Centre — medical oncology (brand owned by Parkway Hospitals Singapore; staffed by SCC doctors)Multidisciplinary medical oncology. Covers consultation, examination, chemotherapy and systemic therapy administration, minor outpatient procedures, prescribing, laboratory and diagnostic orders, and follow-up. Delivered from 9 clinics at Gleneagles Hospital, Mount Elizabeth Hospital, Mount Elizabeth Medical Centre and Mount Elizabeth Novena Specialist Centre.Private-pay and insured adult cancer patients from Singapore and the regionSCC from Nov 2006Consultancy fees under the Consultancy Restatement Agreement with Parkway, plus cost-recovery management fees. Detailed fee formula not publicly disclosed.
Haematology and stem cell transplantationTreatment of adult and paediatric blood disorders and haematologic malignancies, including stem cell transplants. Nurse competency checklists include apheresis (handling blood products).Patients with leukaemia, lymphoma, myeloma and benign blood disordersNot separately datedAs above
Palliative carePalliative healthcare servicesAdvanced-cancer patients and familiesNot separately datedAs above
Singapore Cancer Centre Thu Cuc (Hanoi, Vietnam)Oncology centre operated by Thu Cuc International General Hospital, with consultancy from SCC doctorsVietnamese patientsSet up 2014Profit-sharing agreement. Revenue S$0.03M in FY2024.
TalkMed Shanshui Medical Centre (Beijing, PRC)Private medical centre providing oncology and ancillary support servicesPRC oncology patientsAug 2021Direct patient billing. Consolidated in "China and Hong Kong" revenue (S$2.87M in FY2024).
Sino-Singapore Cancer Centre (Yongchuan, Chongqing, PRC)Category 2A oncology hospital run through the 60:40 JV with Yongchuan District People's Hospital. Implemented a Diagnosis Related Group (DRG) charging system in Dec 2024.Western Chongqing oncology patientsJun 2021Equity-accounted, so revenue is not consolidated. The Group stopped recognising share of losses in 2H 2024 after cumulative losses equalled its investment.
Hong Kong Integrated Oncology Centre (30% associate, divested)Oncology diagnostics and treatment with three clinics. Run with Hong Kong Adventist Hospital Oncology Centre since 2016.Hong Kong and mainland patients2015–Aug 2024Equity-accounted, plus a fixed annual consultancy fee from TalkMed (S$0.275M in FY2022)
Chongqing Medtech Health Management (30% JV)Helps partner hospitals establish internet hospitals and run internet pharmaciesPRC hospitalsFormed Aug 2021Not operational in 2024

Cellular and gene therapy segment

OfferingDescriptionCustomersSinceNotes
CellVec — cGMP lentiviral vectorsManufactures lentiviral vector batches compliant with current Good Manufacturing Practice. Delivered vectors for more than 8 CAR-T products. Its process, quality systems and proprietary plasmids have met Investigational New Drug application requirements internationally, and its products are used in clinical trials.Small biotech companies, research institutes, large pharma. FY2024 revenue by geography: Australia S$1.66M, US S$2.12M, Singapore S$0.84M.Incorporated Aug 2018Contract manufacturing. Revenue is recognised at a point in time or over time depending on contract terms. Facility: freehold GMP unit at 100 Pasir Panjang Road (256 sqm).
CellVec — novel platform viral vector technologiesDevelopment of platform technologies to advance genetic modification of cellular therapies; research into genetic modification of immune cellsInternal / partners2018 onwardReceived SGInnovate funding (FY2024 other income disclosure). Amount not separately disclosed.
BioCell Innovations — humanised CD19-CARAims to widen access to affordable CAR-T products with international collaborators. First product is a humanised CD19-CAR. Initial focus on India, where it is preparing compassionate-use and safety treatment programmes.Patients with B-cell malignancies in the region, India firstIncorporated Jul 2023; operational 2024No revenue in FY2024

Discontinued / divested offerings

OfferingDescriptionPeriodExit
Stem Med (including Stem Med Indonesia and DrSG Cellular Wellness)Stem cell processing, culturing and storage; cellular laboratories and therapeutics clinicsJan 2015 – Oct 2021Sold for fund units (US$811,000). Contingent consideration of up to 7,305 further Class C shares was subject to KPIs by 31 Mar 2023. The fund units were later fully impaired (FY2022–FY2023).

Financial Narrative

All figures are in S$M unless stated. Sources:

  • FY2021, FY2022 and FY2024 full-year results announcements, which supply the comparative years (FY2020 from the FY2021 announcement; FY2023 from the FY2024 announcement)

  • FY2024 Annual Report and FY2024 AGM presentation

Results announcements are unaudited at release; prior-year comparatives within them are audited. TalkMed reports expenses by nature, so it does not report gross profit or cost of sales. Gross profit is therefore not reported and is omitted from the tables rather than estimated.

Income statement

Notes:

  • FY2020 revenue growth uses FY2019 revenue of S$75.92M from the FY2024 Annual Report highlights.

EBIT (derived): PBT − share of associate − share of JVs − interest income + finance costs. It includes other income and impairments. FY2024 EBIT includes the S$2.77M gain on de-recognition of the associate; FY2021 includes the S$1.00M Stem Med disposal gain.

EBITDA (derived): EBIT + depreciation of right-of-use assets and PPE. It is on an SFRS(I) 16 basis, so lease costs sit below EBITDA.

Dividends per share by year: - FY2020: interim 0.60 + final 0.75

  • FY2021: 0.70 + 0.90

  • FY2022: 1.50 + 1.50

  • FY2023: 0.90 + 1.30

  • FY2024: 0.90 interim + 1.40 special; no final

Margins and growth (derived)

Further derived figures:

Revenue CAGR FY2020–FY2024: 5.9%. Measured from the pre-COVID FY2019 base of S$75.92M, the five-year CAGR is only 0.6%.

Company-defined "PAT before extraordinary items": S$27.48M in FY2024 versus S$31.32M in FY2023, down 12.3% (FY2024 AGM presentation).

Attributable profit excluding FY2024 one-offs: (associate gain share S$12.16M and de-recognition gain S$2.77M): about S$28.86M. This is a 10.3% decline versus FY2023 and a 36.9% adjusted net margin.

Balance sheet (31 December)

Notes:

  • TalkMed had no bank borrowings in any year.

  • "Debt" here is lease liabilities plus interest-free or discounted loans from CellVec's non-controlling shareholder to that subsidiary.

  • No goodwill or intangibles were recognised.

  • Non-controlling interests are negative because CellVec, a 60% subsidiary, has a deficit.

Cash flow

Notes:

  • FY2021 operating cash flow and lease principal are the restated comparatives in the FY2022 announcement (S$23.16M and S$2.11M). The FY2021 announcement originally reported S$23.45M and S$2.40M. The difference is a reclassification between operating and financing; the totals are unchanged.

  • FY2022 capex includes the S$4.01M purchase of the Pasir Panjang property.

  • FY2024 investing inflow includes S$14.35M of proceeds from de-recognition of the HKH associate.

Ratios (derived unless noted)

Notes:

  • ROE uses the company's own definition and matches its AGM presentations. The payout ratio is company-reported.

ROIC: is not meaningful. Invested capital (equity + debt − cash) was close to zero or single-digit S$M every year, for example S$2.4M at end-FY2024, so ROIC computes to several hundred percent. ROCE is shown as the closest usable proxy.

Cash conversion cycle: cannot be calculated because the company does not report cost of sales or trade payables separately. Days sales outstanding is shown as the only computable component.

Commentary

Revenue trajectory.

FY2020–FY2021: revenue fell from the FY2019 peak of S$75.9M to S$62.1M in FY2020 and S$60.7M in FY2021. COVID-19 border measures choked off the foreign-patient flows on which SCC depends.

FY2022: the inflection came with Singapore's easing of community and border measures at end-March 2022. Revenue rose 26.1% to S$76.6M, with 2H 2022 alone up 38.4%.

FY2023: revenue reached a record S$83.8M.

FY2024: revenue declined 6.7%. Management attributed this to the Cancer Drug List introduced in September 2022, which tightened what MediShield Life, MediSave and Integrated Shield Plans reimburse and pushed some local patients toward public institutions. Foreign-patient revenue held steady and 2H 2024 recovered to S$45.1M.

Seasonality: the pronounced Q4 seasonality (Q4 FY2023 S$26.5M; Q4 FY2024 S$26.6M) suggests year-end treatment-cycle and billing effects. Management stated that the business is not significantly seasonal, so this pattern deserves diligence attention.

Cost structure.

  • Employee benefits run at 38–43% of revenue. They include doctor remuneration under revenue-sharing schemes, so the cost base is partly variable.

  • Other operating expenses rose from S$4.9M in FY2021 to S$8.9M in FY2024. Drivers were laboratory consumables for CellVec, professional and legal fees (including privatisation-related costs in FY2024), and drug consumables.

Below the operating line.

  • PRC joint-venture losses of S$1.0–1.9M a year and CGT segment losses of S$3.4–9.2M a year were a persistent drag throughout the period.

  • FY2024 PAT rose 44.4% to S$42.4M only because of one-offs: the S$12.16M share of HKH's gain on selling HKIOC and a S$2.77M de-recognition gain. On the company's own adjusted basis, PAT fell 12.3%.

Balance sheet and cash.

  • The group ended each year with S$79–90M in cash and no bank debt.

  • Operating cash flow conversion was strong, at roughly 100–140% of PAT excluding non-cash items.

  • Almost all free cash flow was distributed; FY2022 paid 130% of attributable profit.

  • In FY2024 dividends paid (S$47.8M) exceeded free cash flow (S$28.4M). The gap was funded by the HKH proceeds and a S$7.1M drawdown of cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityInterestRole

Singapore Cancer Centre Pte. Ltd.

100%

Core operating company; supplies doctors and staff to Parkway Cancer Centre

TalkMed Vietnam Pte. Ltd.

100%

Consultancy to Thu Cuc International General Hospital, Hanoi

TalkMed Greater China Pte. Ltd. (TMGC)

100%

PRC holding vehicle

↳ TalkMed China Pte. Ltd.

100%

Holds Beijing interests

↳↳ Beijing Yachuang Siwei Investment Management Co., Ltd.

90% equity plus 10% via contractual arrangements (100% deemed)

Investment and healthcare management

↳↳↳ Beijing Deyi Shanshui Clinic Co., Ltd.

100%

Operates TalkMed Shanshui Medical Centre, Beijing

↳↳ TalkMed Hospital Management (Beijing) Co., Ltd.

100%

Hospital management and advisory

↳ TalkMed Chongqing Pte. Ltd.

100%

Chongqing holding vehicle

↳↳ Sino-Singapore Hospital Management (Chongqing) Co., Ltd.

60% (equity-accounted joint venture)

Operates Sino-Singapore Cancer Centre with Yongchuan District People's Hospital (40%)

↳↳ Chongqing Medtech Health Management Co., Ltd.

30% (joint venture)

Internet hospital and pharmacy services; not operational in 2024

CellVec Pte. Ltd.

60%

Lentiviral vector and CGT manufacturing

BioCell Innovations Pte. Ltd.

60% (StemCord 40%)

CAR-T (humanised CD19-CAR) commercialisation

Hong Kong Integrated Oncology Centre Holdings Ltd.

30% associate; de-recognised 31 Dec 2024

Sold its operating subsidiaries Aug 2024; members' voluntary liquidation commenced in 2025

Revenue by Segment

SegmentFY2020FY2021FY2022FY2023FY2024

Oncology services revenue (SGD Mn)

61.1159.7573.3681.0373.57

Cellular and gene therapy revenue (SGD Mn)

0.120.203.242.764.61

Stem cell services revenue (SGD Mn)

0.910.80000

Total revenue (SGD Mn)

62.1460.7576.6083.7978.18

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Oncology revenue type

Oncology revenue typeFY2020FY2021FY2022FY2023FY2024

Consultancy services (SGD Mn)

39.4237.7948.1751.7544.70

Management fees (SGD Mn)

21.6821.9725.1929.2828.86

Results by Segment

SegmentFY2020FY2021FY2022FY2023FY2024

Oncology services segment profit (SGD Mn)

28.4826.5032.6836.2045.81

Cellular and gene therapy segment profit (SGD Mn)

-9.24-4.54-3.69-6.85-3.41

Stem cell services segment profit (SGD Mn)

-0.72-0.54000

Group profit after tax (SGD Mn)

18.5221.4328.9929.3542.40

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2020FY2021FY2022FY2023FY2024

Oncology revenue YoY growth (%)

0-2.222.810.5-9.2

CGT revenue YoY growth (%)

061.81,526.6-14.767.1

Oncology share of revenue (%)

98.398.495.896.794.1

CGT share of revenue (%)

0.20.34.23.35.9

Oncology segment profit margin (%)

46.644.444.544.762.3

CGT segment profit margin (%)

-7,512.2-2,280.9-113.9-248.1-73.9

Income Statement and Margin Analysis (%)

MetricFY2020FY2021FY2022FY2023FY2024

Revenue (SGD Mn)

62.1460.7576.6083.7978.18

Revenue YoY growth (%)

-18.2-2.226.19.4-6.7

Employee benefits expense (SGD Mn)

24.3826.0429.4433.7833.44

Other operating expenses (SGD Mn)

5.164.865.167.798.89

Depreciation and amortisation (SGD Mn)

3.512.492.542.793.17

Impairment losses (SGD Mn)

3.4100.641.970.02

Operating income / EBIT (SGD Mn, derived)

25.7128.4238.5737.0635.47

EBITDA (SGD Mn, derived)

29.2230.9141.1139.8538.64

Interest income (SGD Mn)

0.710.330.882.612.55

Finance costs (SGD Mn)

0.520.390.350.360.28

Share of associate results (SGD Mn)

-1.04-0.06-0.330.0712.38

Share of joint venture results (SGD Mn)

-0.04-1.02-1.92-1.57-0.69

Profit before tax (SGD Mn)

24.8127.2936.8537.8249.44

Income tax expense (SGD Mn)

6.295.867.868.467.04

Profit after tax (SGD Mn)

18.5221.4328.9929.3542.40

Non-controlling interests share (SGD Mn)

-4.25-3.69-1.56-2.82-1.40

Net income attributable to owners (SGD Mn)

22.7725.1230.5532.1843.79

Basic EPS (S$ cents)

1.731.902.312.433.30

Diluted EPS (S$ cents)

1.721.892.302.423.27

Dividend per share declared for year (S$ cents)

1.351.603.002.202.30

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2020FY2021FY2022FY2023FY2024

EBIT margin (%)

41.446.850.344.245.4

EBITDA margin (%)

47.050.953.747.649.4

Pre-tax margin (%)

39.944.948.145.163.2

PAT margin (%)

29.835.337.835.054.2

Net margin, attributable (%)

36.641.339.938.456.0

Effective tax rate (%)

25.421.521.322.414.2

Employee benefits / revenue (%)

39.242.938.440.342.8

Balance Sheet and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Total assets (SGD Mn)

104.62108.79109.17115.79106.79

Cash and short-term deposits (SGD Mn)

79.4382.1680.5989.9082.78

Trade and other receivables, current (SGD Mn)

10.309.0011.8211.4413.44

Property, plant and equipment (SGD Mn)

2.022.356.004.994.36

Right-of-use assets (SGD Mn)

4.166.174.084.674.36

Goodwill and intangibles (SGD Mn)

00000

Short-term debt incl. current leases and NCI loans (SGD Mn)

1.791.981.854.734.99

Long-term debt incl. non-current leases and NCI loans (SGD Mn)

8.357.045.234.453.73

Total debt (SGD Mn)

10.139.027.099.188.71

Net debt (SGD Mn, negative = net cash)

-69.30-73.15-73.50-80.72-74.07

Total liabilities (SGD Mn)

25.8721.2924.6231.7330.33

Equity attributable to owners (SGD Mn)

83.4390.1888.7190.1283.96

Non-controlling interests (SGD Mn)

-4.68-2.68-4.17-6.06-7.51

Total equity (SGD Mn)

78.7687.5084.5584.0676.46

Working capital / net current assets (SGD Mn)

73.9078.1875.4075.8271.26

NAV per share (S$ cents)

6.336.836.716.806.32

Shares outstanding at year-end (M)

1,318.051,320.111,322.551,325.521,329.14

Cash Flow

MetricFY2020FY2021FY2022FY2023FY2024

Operating cash flow (SGD Mn)

31.2723.1637.1841.7328.80

Capex incl. property purchase (SGD Mn)

1.950.774.330.700.39

Free cash flow (SGD Mn, OCF − capex)

29.3222.3932.8541.0228.41

Lease principal repaid (SGD Mn)

1.562.112.012.132.12

Free cash flow after leases (SGD Mn)

27.7620.2830.8438.9026.29

Dividends paid (SGD Mn)

25.0419.1431.7331.7947.76

Share buybacks (SGD Mn)

00000

Income tax paid (SGD Mn)

5.719.105.897.868.38

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020FY2021FY2022FY2023FY2024

ROE, attributable profit / year-end attributable equity (%)

27.327.934.435.752.2

ROA, PAT / total assets (%)

17.719.726.625.439.7

ROCE, EBIT / (total equity + total debt) (%)

28.929.442.139.841.6

Current ratio (x)

5.246.494.893.783.68

Debt / equity (x)

0.130.100.080.110.11

Net debt / EBITDA (x)

-2.37-2.37-1.79-2.03-1.92

Interest coverage, EBIT / finance costs (x)

49.272.7111.5104.1129.0

Asset turnover, revenue / total assets (x)

0.590.560.700.720.73

Days sales outstanding (days)

60.554.156.349.862.7

Dividend payout, declared / attributable profit (%)

78.284.2130.090.669.7

FY2020 by Quarter

QuarterFY2020FY2021FY2022FY2023FY2024

Q1 revenue (SGD Mn)

15.414.112.918.916.0

Q2 revenue (SGD Mn)

15.314.819.518.917.1

Q3 revenue (SGD Mn)

14.115.320.119.518.5

Q4 revenue (SGD Mn)

17.316.524.126.526.6

Revenue source

Revenue sourceFY2020FY2021FY2022FY2023FY2024

Founder doctors share of revenue (%)

68.264.361.455.551.7

Dr Ang Peng Tiam share of revenue (%)

45.542.440.737.031.8

Number of doctors (Singapore)

1415161715

Number of clinics (Singapore)

99999

Revenue by Region

RegionFY2020FY2021FY2022FY2023FY2024

Singapore (SGD Mn)

61.2659.5872.5078.8071.51

China and Hong Kong (SGD Mn)

0.400.890.792.162.87

Vietnam (SGD Mn)

0.190.130.070.080.03

Australia (SGD Mn)

0.120.092.561.201.66

United States (SGD Mn)

0000.552.12

New Zealand (SGD Mn)

0001.010

Other markets incl. Malaysia, Indonesia, Philippines, India (SGD Mn)

0.170.070.6700

Total (SGD Mn)

62.1460.7576.6083.7978.18

Region Margins & Growth (%) and Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024

Singapore YoY growth (%)

-2.721.78.7-9.3

China and Hong Kong YoY growth (%)

119.6-10.5171.433.0

Vietnam YoY growth (%)

-31.9-43.715.5-63.4

Singapore share of total revenue (%)

98.194.694.091.5

Geography Overview

GeographyOncology consultancyOncology management feesCellular and gene therapyTotal

Singapore

41.9528.720.8471.51

China and Hong Kong

2.740.1302.87

Vietnam

0.010.0200.03

Australia

001.661.66

United States

002.122.12

Total

44.7028.864.6178.18

Share Price History

DatePrice (SGD)Source / note

30 Jan 2014

0.10

IPO placement price S$0.20, adjusted for the 1:1 bonus (derived)

28 Jun 2017

0.74

Intraday price on suspension news (The Edge)

24 Apr 2018

0.70

Close (The Edge)

20 Feb 2024

0.365

Close (The Edge)

5 Apr 2024

0.380

Last undisturbed price before the offer approach (joint announcement)

3-year range to 5 Apr 2024

0.355–0.440

Lowest and highest closing prices, derived from the scheme premia of 28.5% and 3.6%

Dec 2024 (pre-announcement)

0.44

Last traded (The Edge)

Scheme price

0.456

Cash, paid 11 Sep 2025

Valuation Snapshot

MultipleValueBasis

Equity value

S$606.1M

1,329.14M shares × S$0.456

Enterprise value

about S$532.0M

Equity value − cash S$82.8M + leases S$4.4M + NCI loans S$4.3M (31 Dec 2024)

P/E, FY2024 reported

13.8x

Attributable profit S$43.8M

P/E, FY2024 adjusted

21.0x

Attributable profit excluding one-offs, about S$28.9M

P/E, FY2023

18.8x

Attributable profit S$32.2M

EV/EBITDA, FY2024

13.8x

EBITDA S$38.6M; 14.8x excluding the S$2.77M gain

EV/EBITDA, FY2023

13.3x

EBITDA S$39.9M

EV/Sales, FY2024

6.8x

Revenue S$78.2M

P/B, 31 Dec 2024

7.2x

Attributable equity S$84.0M

Dividend yield at scheme price

5.0%

FY2024 DPS 2.30 cents (incl. 1.40 special); 2.0% on ordinary 0.90 cents

Dividend

DividendFY2020FY2021FY2022FY2023FY2024

Interim dividend (cents)

0.600.701.500.900.90

Special dividend (cents)

00001.40

Final dividend (cents)

0.750.901.501.300

Total dividend (cents)

1.351.603.002.202.30

Total dividend declared (SGD Mn, AGM chart)

17.821.139.729.230.5

Payout ratio (%)

78.284.2130.090.669.7

Analyst Conclusions

Guidance and expectations

Management's last guidance (February–April 2025): - Singapore oncology demand stabilising, with steady growth in patient volumes expected in 2025.

  • Foreign-patient demand expected to expand.

  • China growth through collaborations and recruitment.

  • CellVec expected to deliver higher demand and growth in 2025.

Consensus: no consensus forecasts exist; the company is delisted.

FY2025 onward: actual performance is not publicly disclosed.

Bull case (as a Tamarind Health asset or future IPO component)

  1. Margin and cash quality is rare in healthcare services. Derived EBITDA margins of 47–54% and S$29–41M of annual free cash flow on under S$1M of capex make TalkMed a high-quality cash engine to fund Tamarind's regional build-out.

  2. Founder dependence was falling before the deal. The founder share of revenue fell from 68.2% (FY2020) to 51.7% (FY2024), and Dr Ang's from 45.5% to 31.8%. Embedding the practice in a 500-plus-staff platform with sub-specialty groups and a Rare Cancer Centre should continue institutionalising the franchise.

  3. The Cancer Drug List shock appears cyclical rather than structural for the foreign-patient book. Foreign-patient revenue held steady in FY2024. 2H 2024 revenue (S$45.1M) was within 2% of 2H 2023, and Q4 FY2024 (S$26.6M) was a record.

Bear case

  1. Key-person risk was only priced, not removed. The scheme itself made Dr Ang's death or incapacity a termination event. Doctors fell from 17 to 15 in FY2024. Post-deal, founder incentives shift from dividend income to illiquid parent equity.

  2. Organic growth is weak. FY2024 revenue was only 3% above FY2019. Excluding one-offs, FY2024 attributable profit fell about 10%. Every non-core venture since IPO (Hong Kong, China, stem cells, CGT) has generated impairments or losses, with the one exception of the HKIOC sale.

  3. Structural policy and price headwinds: the Cancer Drug List and Integrated Shield Plan rider changes, a strong Singapore dollar, and lower-cost Thai and Malaysian alternatives cap Singapore pricing. Dependence on the Parkway contract leaves bargaining power with IHH.

Catalysts and monitorables (next 12 months)

  • Any Tamarind Health capital-markets activity, including the SGX relisting option flagged in December 2024.

  • Renewal or renegotiation of the Parkway Consultancy Restatement Agreement, and the founder doctors' new service agreements.

  • Doctor headcount and recruitment within the TalkMed practice.

  • Ministry of Health revisions to the Cancer Drug List and Integrated Shield Plan rules.

  • Progress of CellVec revenue and BioCell's India CAR-T programme.

  • Performance of the China centres after the 2025 premises relocation and DRG billing in Chongqing.

  • Tamarind disclosures on network patient volumes, and any further acquisitions or disposals of non-core TalkMed assets (CGT, China).

Concluding analyst verdict

TalkMed's eleven-and-a-half years as a listed company tell a consistent story. At its core was an outstanding professional-services franchise, wrapped in a corporate structure that never found a second engine.

The Parkway Cancer Centre practice was the economic substance. Built by Dr Ang Peng Tiam and three fellow founders, it generated derived EBITDA margins of roughly 50%, carried no bank debt, held S$80–90M of cash, and returned more than S$155M in dividends over FY2020–FY2024 alone.

Shareholders paid for that quality with three concentrations:

People: the founders still generated over half of revenue in FY2024.

Partner: effectively all Singapore oncology revenue ran through Parkway.

Policy: the Cancer Drug List visibly dented FY2024 revenue.

Diversification into Hong Kong, China, stem cells and cell and gene therapy consumed management attention and capital. It produced recurring losses; only the Hong Kong exit delivered a gain.

The S$0.456 scheme price valued the equity at about S$606M. That is roughly 14x trailing EBITDA and 21x one-off-adjusted earnings, a 20% premium to the undisturbed price. For minority holders confined by negligible liquidity, the deal was fair: it offered an exit near the top of the three-year trading range.

For Tamarind Health, TalkMed is the logical Singapore anchor. It combines Parkway Cancer Centre's referral franchise with OncoCare and sister practices to create the region's largest private, doctor-led oncology network. Strategically, the transaction converts key-person risk into a platform-retention problem. It is managed through founder reinvestment, board seats and renewed service agreements rather than eliminated.

The investment case now rests on four execution tests:

  • Can Tamarind institutionalise sub-specialty care and the Rare Cancer Centre fast enough?

  • Can it keep the founder doctors engaged?

  • Can it hold Parkway economics steady?

  • Can it lift growth above the near-flat FY2019–FY2024 trajectory?

Verdict: a high-quality, low-growth cash franchise whose value now depends on platform integration. Monitor any relisting of the combined entity closely; TalkMed alone was not a compelling growth story.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationAge (AR2024)

Dr Ang Peng Tiam

Executive Director and Group CEO; Medical Director and Senior Consultant, Parkway Cancer Centre (Mount Elizabeth)

Director since 10 Sep 2013

Founding Head of Medical Oncology at Singapore General Hospital (1991–1997); Clinical Associate Professor; fellowships at MD Anderson and Stanford

MBBS (Singapore); MMed Internal Medicine (NUS); FAMS, FACP, FRCP (Edin), FRCP (Lond)

66

Dr Khoo Kei Siong

Group COO; Alternate Director to Dr Ang; Deputy Medical Director, Parkway Cancer Centre (Gleneagles)

Executive Director until 31 Dec 2023; alternate director thereafter

Senior Consultant at National Cancer Centre Singapore (1999–2004); Head of Medical Oncology there (2001–2004)

MBBS (Singapore); MMed Internal Medicine (NUS); FRCP (Edin); FAMS

63

Lee Boon Yong

Group CFO; Company Secretary

Since 1 Sep 2014

nTan Corporate Advisory; EY (audit, transaction advisory)

B.Acc (NTU, 2002); ISCA; CA ANZ

—

“—” = not publicly disclosed.

Board of Directors

NameRoleFirst appointedBackgroundAge

S. Chandra Das

Non-Independent Non-Executive Chairman; RC member

23 Dec 2013

Former MP (1980–1996); former chairman of the Trade Development Board and NTUC FairPrice; Non-Resident High Commissioner to Sri Lanka; NTU Pro-Chancellor

84

Dr Ang Peng Tiam

Executive Director and CEO; NC member

10 Sep 2013

See above

66

Sitoh Yih Pin

Non-Independent Non-Executive Director; ARC member

23 Dec 2013

Chartered Accountant; MP for Potong Pasir

61

Prof Leong Ching Ching

Independent Director; RC Chairperson

1 Oct 2021

Vice Provost (Student Life), NUS; Lee Kuan Yew School of Public Policy

55

Peter Sim Swee Yam

Independent Director; NC Chairman; ARC member

1 Jan 2024

Lawyer with more than 42 years of practice (Sim Law Practice); independent director of Singapore Land Group

69

Lam Kok Shang

Independent Director; ARC Chairman; NC member

1 Jan 2024

Former KPMG Singapore partner (head of Indirect Tax); GST Board of Review member 2013–2018

61

Dr Tan Khai Tong

Independent Director; RC member

1 Jan 2024

Consultant endocrinologist; National Healthcare Group board member 2014–2023

66

Directors' Remuneration

MetricFY2020FY2021FY2022FY2023FY2024

Total key management compensation (SGD Mn)

7.508.188.608.618.47

Paid to directors of the Company (SGD Mn)

6.206.216.336.336.34

Paid to other key management (SGD Mn)

1.291.962.272.282.13

Directors' fees, Company and subsidiaries (SGD Mn)

0.380.390.500.500.51

Major Shareholders

HolderShares%

Ladyhill Holdings Pte. Ltd. (72% owned by Dr Ang; Dr Ang and spouse Mdm Chua Siok Lin deemed interested)

858,912,00064.62

Dr Khoo Kei Siong

99,360,0007.48

Dr Teo Cheng Peng

98,256,0007.39

Dr Lim Hong Liang

47,472,0003.57

Founder doctors and Ladyhill combined

1,104,000,00083.06

Other directors combined (Das via spouse, Prof Leong, Dr Tan)

1,460,3000.11

Free float (derived)

about 224M

about 16.8

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypePositioning vs TalkMed

Private oncology, Singapore

OncoCare Medical (now a sister company under Tamarind)

Private group practice

Formerly the closest rival; now consolidated with TalkMed under one parent

Private oncology, Singapore

Icon Cancer Centre (Singapore)

Private oncology/radiotherapy chain

Integrated radiation and medical oncology.

Private oncology, Singapore

Raffles Cancer Centre (Raffles Medical Group, SGX: BSL)

Hospital-based

Vertically integrated hospital competitor

Private oncology, Singapore

Thomson Medical Group (SGX: A50) oncology services

Hospital and clinic group

Smaller oncology presence

Private hospital platform

IHH Healthcare / Parkway Pantai (Bursa: IHH)

Hospital owner

Both landlord/partner and potential competitor if it employs oncologists directly

Public oncology, Singapore

National Cancer Centre Singapore (SingHealth)

Public

Lower-cost alternative; benefits from Cancer Drug List and insurer shifts

Public oncology, Singapore

National University Cancer Institute, Singapore (NUHS)

Public

As above

Regional private oncology

TE Asia Healthcare Partners (TPG-backed)

Specialty platform

Oncology, cardiology and orthopaedics across SE Asia and Hong Kong

Regional medical tourism, Thailand

Bumrungrad International; Bangkok Dusit Medical Services

Hospital groups

Lower-cost destinations; the FY2024 Annual Report notes Thailand and Malaysia as cheaper competitors

Regional medical tourism, Malaysia

Sunway Medical Centre; Gleneagles/Pantai (IHH); Beacon Hospital

Hospital groups

Same competitive dynamic

Hong Kong oncology

Hong Kong Integrated Oncology Centre (now New Frontier)

Private

Former associate

CGT CDMO

Global and regional viral vector CDMOs

Contract manufacturers

CellVec is sub-scale. Named competitors are not disclosed by the company.

Peer Comparison FY2024

MetricTalkMed FY2024 (Dec)Raffles Medical FY2024 (Dec)IHH Healthcare FY2024 (Dec)Thomson Medical FY2024 (Jun)

Revenue

S$78.2M

S$751.6M

RM24.38B

S$351.2M

Revenue growth

-6.7%+6.3%+16%-1.3%

EBITDA

S$38.6M (derived)

S$125.7M

about RM5.44B

S$102.4M

EBITDA margin

49.4% (derived)

16.7% (derived)

about 22% (derived)

29.2% (derived)

Net margin

56.0% reported; about 36.9% adjusted

8.3% (PATMI)

about 10.9% headline (derived)

5.6% (PAT, derived)

Balance sheet

Net cash S$74.1M; no borrowings

Not analysed

Not analysed

Net debt to EBITDA rose to 9.2x (Jun 2024, per FSMOne)

Recent Developments

As a private company since September 2025, TalkMed issues no regulatory filings.

Not publicly disclosed post-delisting: * financial results, layoffs or hiring, guidance, contract changes with Parkway, litigation, and leadership changes at the TalkMed entity level.

Company Snapshot

$58.5M

Revenue

270

Employees

$447M

Market Cap

2013

Founded

Mount Elizabeth, Singapore

Headquarters

SWOT Analysis

Strengths

  • Exceptional margins: derived EBITDA margin of 47–54% in FY2020–FY2024, versus about 17% for Raffles Medical and about 22% for IHH in FY2024.
  • Debt-free, cash-rich balance sheet: cash of S$82.8M at 31 December 2024 against no bank borrowings. Net cash averaged S$74M over five years.
  • High returns: ROE of 34–36% in FY2022–FY2023 and 52.2% in FY2024 (company-reported).
  • Regional referral franchise: foreign patients exceed half of SCC's patient load (FY2024 Annual Report). Foreign-patient revenue held stable even through the Cancer Drug List shock.
  • Strong cash generation and shareholder returns: cumulative dividends paid of S$155.5M over FY2020–FY2024, exceeding cumulative free cash flow of S$154.0M (derived).
  • Deep clinical bench at founder level: four founder doctors with SGH and NCCS leadership pedigrees anchored a 15–17-doctor team.

Weaknesses

  • Key-person concentration: Dr Ang generated 31.8% of FY2024 revenue, and the founders 51.7%. The 2017–2018 suspension showed the sensitivity: Q1 2018 revenue fell 25.7% year on year (The Edge).
  • Counterparty concentration: nearly all Singapore oncology revenue flows through Parkway Hospitals Singapore under one agreement.
  • Loss-making diversification: the CGT segment lost S$27.7M after tax over FY2020–FY2024. PRC JVs generated S$5.2M of cumulative share of losses through FY2024, with the investment written down to S$0.15M.
  • Stagnant multi-year growth: FY2024 revenue of S$78.2M was only 3.0% above FY2019's S$75.9M. The FY2016 peak was S$68.9M.
  • Doctor attrition risk: doctor headcount fell from 17 (FY2023) to 15 (FY2024). The scheme contained a specific condition protecting against loss of doctors generating 15% or more of revenue.
  • Thin trading liquidity: average daily volume was about 0.001% of shares, which constrained valuation while listed.

Opportunities

  • Platform scale: Tamarind's 36-centre network across six markets enables cross-referral and sub-specialisation (October 2025 press release).
  • Medical-tourism recovery: management expected expanding foreign demand in 2025 as connectivity improves.
  • China ageing demand: Beijing and Chongqing patient numbers grew in 2024. China and Hong Kong revenue rose 33% to S$2.87M.
  • CGT momentum: CellVec revenue rose 67% to S$4.61M in FY2024 and serves more than 8 CAR-T programmes, with US revenue rising to S$2.12M.
  • Affordable CAR-T in India: BioCell's CD19-CAR addresses a large unmet need.
  • Possible relisting: the combined entity may consider an SGX listing, offering a path to a scarcity-value IPO.

Threats

  • Health-financing reform: the Cancer Drug List cut FY2024 oncology revenue by S$7.46M.
  • Regional price competition: Thailand and Malaysia offer cheaper care, and a strong Singapore dollar widens the gap (FY2024 Annual Report).
  • Partner economics: Parkway's owner IHH is itself expanding oncology capacity, and the consultancy terms could be renegotiated.
  • Integration risk under PE ownership: combining doctor-led practices with different cultures and remuneration schemes.
  • CGT market volatility: demand for vectors fell sharply during COVID-19, prompting impairments in FY2020–FY2022.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 Dec 2024Joint announcement of the scheme at S$0.456 per share. 20.0% premium to last undisturbed price of S$0.380 (5 Apr 2024); 22.6% premium to 1-month VWAP.Change of control initiated
23 Dec 2024Founder doctors and Ladyhill give irrevocable undertakings (83.06%) and sign rollover and subscription agreementsEffectively guaranteed approval
9 Jan 2025KPMG Corporate Finance appointed independent financial adviser (per AGM Q&A)Process step
25 Feb 2025FY2024 results: revenue S$78.2M (−6.7%); attributable profit S$43.8M (+36.1%); no final dividend because of the schemeLast full-year results as a listed company
Early 2025HKH begins members' voluntary liquidationHong Kong exit finalised
8–23 Mar 2025Title sponsor of SCS-TalkMed Relay for Life; about S$1.35M raisedCommunity engagement
Apr 2025FY2024 Annual Report and eighth Sustainability Report publishedLast annual report
29 Apr 202512th AGM. Re-election of Das, Ang and Tan; EY re-appointed; FY2025 directors' fees S$510k. Shareholder questions on IFA timing.Governance continuity
17 Jun 2025Court grants leave to convene the scheme meetingLegal process
27 Jun 2025CCCS clearance condition satisfiedAntitrust cleared; the combination unites Parkway Cancer Centre doctors with OncoCare and other Tamarind practices
30 Jun 2025Composite document (scheme plus management arrangements, with IFA advice) disseminatedShareholder vote preparation
15 Jul 2025Scheme meeting approves the scheme (about 89.1% in favour, per Business Times as summarised by Techleap)Shareholder approval
18 Aug 2025Court sanctions the schemeLegal approval
21 Aug 2025SGX in-principle approval for delistingRegulatory approval
2 Sep 2025Scheme effectiveOwnership transfers to TW Troy
11 Sep 2025Scheme consideration paidCompletion
15 Sep 2025Delisted from the SGX Mainboard, about 11.6 years after the January 2014 IPOEnd of public-company status
15 Oct 2025Tamarind Health press release: 36 centres, six markets, more than 180,000 visits a year, more than 500 doctors and staff; Dr Ang joins the Tamarind board and retains equityIntegration framing
Oct 2025 onwardTamarind communications describe a nine-clinic, 22-specialist Hong Kong network (OncoCare Hong Kong); timing not precisely verifiedNetwork context
Sep 2026Tamarind Health launches the Rare Cancer CentreFirst visible cross-network clinical product including TalkMed specialists

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from SGD 62.1 Mn in FY2020 to SGD 78.2 Mn in FY2024.
TalkMed Group Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2020FY2021FY2022FY2023FY2024
Revenue62.160.876.683.878.2
Q1 revenue15.414.112.918.916
Q2 revenue15.314.819.518.917.1
Q3 revenue14.115.320.119.518.5
Q4 revenue17.316.524.126.526.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. TalkMed FY2024 full-year results announcement (25 Feb 2025) (links.sgx.com)
  2. TalkMed FY2024 Annual Report (links.sgx.com)
  3. TalkMed FY2024 AGM presentation (29 Apr 2025) (links.sgx.com)
  4. TalkMed FY2022 full-year results announcement (links.sgx.com)
  5. TalkMed FY2021 full-year results announcement (links.sgx.com)
  6. Joint announcement on proposed privatisation (23 Dec 2024) (links.sgx.com)
  7. Privatisation press release (23 Dec 2024) (links.sgx.com)
  8. Scheme effective-date announcement (2 Sep 2025) (links.sgx.com)
  9. CCCS approval announcement (27 Jun 2025) (links.sgx.com)
  10. Delisting summary (15 Sep 2025) (www-web.itiger.com)
  11. HKIOC disposal completion (8 Aug 2024) (links.sgx.com)
  12. BDA Partners on HKIOC sale to New Frontier (bdapartners.com)
  13. IPO placement results (30 Jan 2014) (links.sgx.com)
  14. SGX welcome release (30 Jan 2014) (links.sgx.com)
  15. Bonus share issue (May 2017) (links.sgx.com)
  16. The Edge on Dr Ang suspension (28 Jun 2017) (theedgemalaysia.com)
  17. The Edge on Dr Ang resuming duties (Mar 2018) (alfi.dev.theedgesingapore.com)
  18. The Edge on the Tamarind offer (testing.dev.theedgesingapore.com)
  19. Shareholder approval summary (Jul 2025) (finder.techleap.nl)
  20. Tamarind Health press release (15 Oct 2025) (tirto.id)
  21. Tamarind Health Rare Cancer Centre (Sep 2026) (biospectrumasia.com)
  22. 65 Equity Partners portfolio page (65equitypartners.com)
  23. Raffles Medical FY2024 media release (rafflesmedicalgroup.com)
  24. IHH Healthcare Annual Report 2024 (insage.com.my)
  25. Kenanga IHH results note (Feb 2025) (kenanga.com.my)
  26. Thomson Medical FY2024 media release (links.sgx.com)
  27. FSMOne on Thomson Medical debt metrics (secure.fundsupermart.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.